TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

Teva Pharmaceutical Industries Limited TEVA and its partner, Biolojic Design Ltd., announced that TEVA has initiated investigational new drug or IND-enabling studies on BD9, a dual-specific multibody targeting both TSLP (Thymic stromal lymphopoietin) and IL-13 for the treatment of TH2-driven inflammatory diseases like asthma and atopic dermatitis.

TEVA holds an exclusive license to develop BD9, which acts by simultaneously blocking IL-13 and TSLP, two key drivers of TH2-driven inflammation. The candidate has the potential to improve outcomes for patients with inflammatory diseases like asthma and atopic dermatitis, also known as eczema.

Per the latest agreement, Teva is responsible for the development of BD9 globally, while Biolojic is entitled to receive certain regulatory and commercial-based milestone payments. BD9 is being developed using Biolojic’s multibody platform that can generate antibodies targeting multiple disease areas.

Shares of Teva were up 4.4% on May 27 following the announcement of the news.

So far this year, shares of Teva have lost 19.6% compared with the industry’s decline of 15.8%.

FDA Grants Fast Track Tag to TEVA's TEV-53408

In a separate press release, Teva announced that the FDA has granted Fast Track designation to its anti-IL-15 antibody, TEV-53408, for the treatment of people with celiac disease on a gluten-free diet.

The FDA’s Fast Track designation is intended to speed up the development and review of drugs that treat serious conditions and fulfill unmet medical needs.

A phase IIa study is currently evaluating the safety and efficacy of TEV-53408 for treating adults with celiac disease.

Teva continues to make good progress with its innovative pipeline, which is mostly in the neuroscience and immunology areas.

TEVA's Zacks Rank & Stocks to Consider

Teva currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Lexicon Pharmaceuticals LXRX, Chemomab Therapeutics CMMB and Amarin AMRN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In the past 60 days, estimates for Lexicon’s loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 6.6%.

LXRX’s earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%.

In the past 60 days, estimates for Chemomab Therapeutics’ loss per share have narrowed from 70 cents to 60 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 80 cents to 70 cents. Year to date, shares of CMMB have declined 22.7%.

CMMB’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 5.00%.

In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 17.1%.

AMRN’s earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research